XM tillhandahåller inte tjänster till personer bosatta i USA.

U.S. Aerovate Therapeutics, Boeing, Wingstop



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>U.S. RESEARCH ROUNDUP-Aerovate Therapeutics, Boeing, Wingstop</title></head><body>

June 18 (Reuters) -Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aerovate Therapeutics, Boeing and Wingstop, on Tuesday.


HIGHLIGHTS


* Aerovate Therapeutics Inc AVTE.O: TD Cowen cuts to hold from buy

* Boeing BA.N: RBC cuts target price to $210 from $215

* Mirum Pharmaceuticals Inc MIRM.O: Evercore ISI raises target price to $62 from $53

* Transdigm Group Inc TDG.N: RBC raises target price to $1,500 from $1,400

* Wingstop Inc WING.O: Stifel raises target price to $460 from $420

Following is a summary of research actions on U.S. companies reported by Reuters on Tuesday. Stock entries are in alphabetical order.


* Aaron's Company Inc AAN.N: Truist Securities raises target price to $10.10 from $8

* Abbvie Inc ABBV.N: Piper Sandler raises target price to $190 from $185

* Addus Homecare Corp ADUS.O: TD Cowen raises target price to $128 from $119

* Aerovate Therapeutics Inc AVTE.O: Guggenheim cuts to neutral

* Aerovate Therapeutics Inc AVTE.O: TD Cowen cuts to hold from buy

* Apple Inc AAPL.O: JP Morgan raises target price to $245 from $225

* Arhaus Inc ARHS.O: Jefferies raises target price to $22 from $19

* Beyond Inc BYON.N: BofA Global Research cuts price objective to $15.5 from $19

* Beyond Inc BYON.N: Jefferies cuts target price to $15 from $18

* Boeing BA.N: RBC cuts target price to $210 from $215

* Cardlytics CDLX.O: Northland Capital initiates coverage with outperform rating; PT $14

* Carmax Inc KMX.N: Mizuho cuts target price to $72 from $75

* Carmax Inc KMX.N: Truist Securities cuts target price to $66 from $72

* Casella Waste Systems Inc CWST.O: Stifel raises target price to $110 from $105

* Celldex Therapeutics CLDX.O: Stifel initiates coverage with buy rating; PT $58

* Chegg Inc CHGG.N: Jefferies cuts target price to $2.50 from $4

* Chegg Inc CHGG.N: Northland Capital cuts target price to $7 from $10

* Chipotle Mexican Grill CMG.N: Argus Research raises PT to $3,888 from $3,668

* Chromocell Therapeutics CHRO.A: Alliance Global Partners initiates coverage with buy rating; PT $8.50

* Clean Harbors Inc CLH.N: Stifel raises target price to $240 from $230

* Constellation Energy Corp CEG.O: UBS raises target price to $249 from $227

* Corning Inc GLW.N: Mizuho raises target price to $42 from $36

* Corteva Inc CTVA.N: Mizuho cuts target price to $60 from $61

* Darden Restaurants Inc DRI.N: Deutsche Bank cuts target price to $180 from $183

* Digitalbridge Group Inc DBRG.N: Deutsche Bank cuts target price to $17 from $21

* Digitalbridge Group Inc DBRG.N: KBW cuts target price to $17.75 from $18.5

* Energy Transfer LP ET.N: Mizuho raises target price to $20 from $19

* Equitable Holdings Inc EQH.N: UBS cuts to neutral from buy

* Equitable Holdings Inc EQH.N: UBS raises target price to $43 from $40

* Geovax Labs GOVX.O: H.C. Wainwright adjusts PT to $8 to reflect 1-for-15 reverse stock-split

* Granite Ridge Resources Inc GRNT.N: Gerdes Energy Research initiates with buy rating

* Granite Ridge Resources Inc GRNT.N: Gerdes Energy Research initiates with PT $7

* Humacyte Inc HUMA.O: TD Cowen raises target price to $7.5 from $6

* Innoviva Inc INVA.O: Cantor Fitzgerald initiates coverage with overweight rating

* Intra-Cellular Therapies Inc ITCI.O: RBC raises target price to $103 from $96

* Juniper Networks Inc JNPR.N: Argus Research raises to buy from hold

* Knife River Corp KNF.N: Stephens initiates coverage with overweight rating; PT $85

* Kroger Co KR.N: BMO raises target price to $60 from $58

* Kroger Co KR.N: BMO raises to outperform from market perform

* Levi Strauss & Co LEVI.N: TD Cowen raises target price to $26 from $23

* Loar Holdings Inc LOAR.N: RBC raises target price to $65 from $60

* McCormick & Company Inc MKC.N: Jefferies cuts target price to $73 from $77

* Micron Technology Inc MU.O: BofA Global Research adds stock to its U.S. 1 list

* Micron Technology Inc MU.O: Stifel raises target price to $165 from $140

* Micron Technology Inc MU.O: Wedbush raises target price to $170 from $130

* Mirum Pharmaceuticals MIRM.O: Citigroup raises target price to $64 from $38

* Mirum Pharmaceuticals MIRM.O: Evercore ISI raises target price to $62 from $53

* Mirum Pharmaceuticals MIRM.O: JP Morgan raises target price to $39 from $31

* Mirum Pharmaceuticals MIRM.O: Morgan Stanley raises target price to $57 from $53

* Mirum Pharmaceuticals MIRM.O: Raymond James raises target price to $71 from $60

* Montrose Environmental Group Inc MEG.N: Stifel raises target price to $56 from $51

* Motorola Solutions Inc MSI.N: Morgan Stanley raises target price to $365 from $335

* Nurix Therapeutics Inc NRIX.O: H.C. Wainwright raises target price to $26 from $19

* Nvidia Corp NVDA.O: Rosenblatt Securities adjusts price target to $200 to reflect 10-for-1 stock split

* Nvidia Corp NVDA.O: Wells Fargo raises target price to $155 from $125

* Oge Energy Corp OGE.N: Barclays raises target price to $35 from $34

* Old Dominion Freight Line Inc ODFL.O: Jefferies cuts target price to $185 from $200

* Omega Therapeutics Inc OMGA.O: Raymond James initiates coverage with outperform rating; PT $12

* Oracle Corp ORCL.N: Argus Research raises target price to $159 from $145

* Ovid Therapeutics Inc OVID.O: BTIG cuts target price to $5 from $11

* Ovid Therapeutics Inc OVID.O: Citigroup cuts target price to $1.2 from $3.5

* Ovid Therapeutics Inc OVID.O: H.C. Wainwright cuts target price to $3 from $9

* Ovid Therapeutics Inc OVID.O: Oppenheimer cuts to perform from outperform

* Perspective Therapeutics CATX.A: Oppenheimer adjusts target price to $19 from $2 to reflect 1-for-10 reverse stock split

* Pilgrims Pride PPC.O: Argus Research initiates coverage with buy rating; PT $41

* Portillos Inc PTLO.O: Guggenheim cuts target price to $18 from $22

* Portillos Inc PTLO.O: Jefferies cuts target price to $18 from $19

* Praxis Precision Medicines Inc PRAX.O: Guggenheim initiates coverage With Buy rating; PT $155

* Primo Water Corp PRMW.N: CIBC raises target price to $26 from $24

* Primo Water Corp PRMW.N: JP Morgan raises target price to $26 from $24

* Primo Water Corp PRMW.N: Raymond James raises target price to $26 from $23

* Primo Water Corp PRMW.N: TD Cowen raises target price to $32 from $30

* Q2 Holdings Inc QTWO.N: Truist Securities raises target price to $68 from $65

* Qiagen NV QGEN.N: UBS raises target price to $46 from $44

* Quantum Corp QMCO.O: Northland Capital cuts target price to $0.50

* Quinstreet Inc QNST.O: Craig-Hallum raises target price to $22 from $20

* Quinstreet Inc QNST.O: Craig-Hallum raises to buy from hold

* RB Global Inc RBA.N: CIBC initiates coverage with outperformer rating; PT $95

* Reddit RDDT.N: Needham raises target price to $75 from $63

* Repligen Corp RGEN.O: Guggenheim initiates coverage With Neutral rating

* Republic Services Inc RSG.N: Stifel raises target price to $215 from $210

* Silk Road Medical Inc SILK.O: Piper Sandler raises PT to $27.50 from $20

* Steel Dynamics Inc STLD.O: BMO cuts target price to $135 from $140

* Sunoco LP SUN.N: Citigroup raises to buy from neutral

* Teradyne Inc TER.O: UBS raises target price to $170 from $130

* The Hershey Company HSY.N: Barclays cuts target price to $204 from $210

* Third Harmonic Bio Inc THRD.O: Stifel initiates coverage with buy rating; PT $23

* Transdigm Group Inc TDG.N: RBC raises target price to $1,500 from $1,400

* Triumph Financial Inc TFIN.O: KBW raises target price to $75 from $68

* Urban Outfitters Inc URBN.O: Barclays raises target price to $52 from $50

* Viasat Inc VSAT.O: Morgan Stanley cuts target price to $26 from $28

* Waste Management Inc WM.N: Stifel raises target price to $231 from $227

* Williams Companies Inc WMB.N: Truist Securities raises target price to $42 from $40

* Wingstop Inc WING.O: Stifel raises target price to $460 from $420

* Wolfspeed Inc WOLF.N: Mizuho raises target price to $28 from $27

* Xponential Fitness Inc XPOF.N: Guggenheim raises target price to $20 from $18

* Zentalis Pharmaceuticals Inc ZNTL.O: H.C. Wainwright cuts target price to $20 from $40

* Zentalis Pharmaceuticals Inc ZNTL.O: Wedbush cuts to underperform from neutral

* Zentalis Pharmaceuticals Inc ZNTL.O: Wedbush cuts target price to $4 from $15


(Compiled by Bengaluru Newsroom)

</body></html>

Ansvarsfriskrivning: XM Group-enheter tillhandahåller sin tjänst enbart för exekvering och tillgången till vår onlinehandelsplattform, som innebär att en person kan se och/eller använda tillgängligt innehåll på eller via webbplatsen, påverkar eller utökar inte detta, vilket inte heller varit avsikten. Denna tillgång och användning omfattas alltid av i) villkor, ii) riskvarningar och iii) fullständig ansvarsfriskrivning. Detta innehåll tillhandahålls därför uteslutande som allmän information. Var framför allt medveten om att innehållet på vår onlinehandelsplattform varken utgör en uppmaning eller ett erbjudande om att ingå några transaktioner på de finansiella marknaderna. Handel på alla finansiella marknader involverar en betydande risk för ditt kapital.

Allt material som publiceras på denna sida är enbart avsett för utbildnings- eller informationssyften och innehåller inte – och ska inte heller anses innehålla – rådgivning och rekommendationer om finansiella frågor, investeringsskatt eller handel, dokumentation av våra handelskurser eller ett erbjudande om, eller en uppmaning till, en transaktion i finansiella instrument eller oönskade finansiella erbjudanden som är riktade till dig.

Tredjepartsinnehåll, liksom innehåll framtaget av XM såsom synpunkter, nyheter, forskningsrön, analyser, kurser, andra uppgifter eller länkar till tredjepartssajter som återfinns på denna webbplats, tillhandahålls i befintligt skick, som allmän marknadskommentar, och utgör ingen investeringsrådgivning. I den mån som något innehåll tolkas som investeringsforskning måste det noteras och accepteras att innehållet varken har varit avsett som oberoende investeringsforskning eller har utarbetats i enlighet med de rättsliga kraven för att främja ett sådant syfte, och därför är att betrakta som marknadskommunikation enligt tillämpliga lagar och föreskrifter. Se till så att du har läst och förstått vårt meddelande om icke-oberoende investeringsforskning och riskvarning om ovannämnda information, som finns här.

Riskvarning: Ditt kapital riskeras. Hävstångsprodukter passar kanske inte alla. Se vår riskinformation.